The expiry of the Semaglutide patent in India has triggered a high-stakes entry of domestic pharma majors into the GLP-1 therapy space, setting the stage for intense price competition and wider patient access. With type 2 diabetes and obesity emerging as major public health challenges, companies are racing to capture a share of what is […]